Literature DB >> 18814973

Blocking of beta-2 adrenergic receptors hastens recovery from hypoglycemia-associated social withdrawal.

Min Jung Park1, Christopher B Guest, Meredith B Barnes, Jonathan Martin, Uzma Ahmad, Jason M York, Gregory G Freund.   

Abstract

OBJECTIVE: Hypoglycemia is associated with a variety of adverse behaviors including fatigue, confusion and social withdrawal. While these clinical symptoms are well characterized, the mechanism of their cause is not understood. Here we investigated how insulin-induced hypoglycemia causes social withdrawal. RESEARCH DESIGN AND METHODS: Male 8-12-week-old C57BL/6J mice were injected intraperitoneally (IP) with or without and/or insulin, norepinephrine (NE) and epinephrine (Epi), terbutaline and butoxamine with subsequent measurement of blood glucose, social withdrawal and plasma catecholamines.
RESULTS: Insulin generated (0.75h post-injection) significant hypoglycemia with blood glucose nadirs of 64+/-4 and 48+/-5mg/dl for 0.8 and 1.2units/kg of insulin, respectively. Insulin (0.8 or 1.2units/kg) caused near total social withdrawal at 0.75h with full recovery not occurring until 4h (0.8units/kg) or 8h (1.2units/kg) post-insulin injection. Insulin also caused a marked elevation in plasma catecholamines. Basal 12h fasting NE and Epi were 287+/-38 and 350+/-47pg/ml, respectively. Insulin at 0.8units/kg increased plasma NE and Epi to 994+/-73 and 1842+/-473pg/ml, respectively. Administration of exogenous NE or Epi caused social withdrawal similar in magnitude to insulin. Importantly, administration of the beta-2 adrenergic receptor agonist terbutaline also caused social withdrawal while administration of the beta-2 adrenergic receptor antagonist butoxamine blocked NE-induced social withdrawal. Finally, butoxamine blocked insulin-induced social withdrawal.
CONCLUSIONS: These data demonstrate that hypoglycemia-associated social withdrawal is dependent on catecholamines via a beta-2 receptor-mediated pathway.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18814973      PMCID: PMC2636565          DOI: 10.1016/j.psyneuen.2008.08.005

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  43 in total

1.  Effects of chronic exposure to stressors on avoidance-escape behavior and on brain norepinephrine.

Authors:  J M Weiss; H I Glazer; L A Pohorecky; J Brick; N E Miller
Journal:  Psychosom Med       Date:  1975 Nov-Dec       Impact factor: 4.312

2.  Neuropsychological profiles of children with type 1 diabetes 6 years after disease onset.

Authors:  E A Northam; P J Anderson; R Jacobs; M Hughes; G L Warne; G A Werther
Journal:  Diabetes Care       Date:  2001-09       Impact factor: 19.112

Review 3.  Morbidity of hypoglycemia in type 1 diabetes.

Authors:  Brian M Frier
Journal:  Diabetes Res Clin Pract       Date:  2004-09       Impact factor: 5.602

4.  Acebutolol, atenolol, and propranolol and metabolic responses to acute hypoglycaemia in diabetics.

Authors:  S P Deacon; A Karunanayake; D Barnett
Journal:  Br Med J       Date:  1977-11-12

Review 5.  Cytokine-induced sickness behaviour: a neuroimmune response to activation of innate immunity.

Authors:  Robert Dantzer
Journal:  Eur J Pharmacol       Date:  2004-10-01       Impact factor: 4.432

6.  Reversible inactivation of the dorsal vagal complex blocks lipopolysaccharide-induced social withdrawal and c-Fos expression in central autonomic nuclei.

Authors:  Françoise A Marvel; Chiao-Chi Chen; Nadia Badr; Ron P A Gaykema; Lisa E Goehler
Journal:  Brain Behav Immun       Date:  2004-03       Impact factor: 7.217

7.  Insulin receptor substrate-2-dependent interleukin-4 signaling in macrophages is impaired in two models of type 2 diabetes mellitus.

Authors:  Matthew E Hartman; Jason C O'Connor; Jonathan P Godbout; Kyle D Minor; Valerie R Mazzocco; Gregory G Freund
Journal:  J Biol Chem       Date:  2004-04-27       Impact factor: 5.157

8.  CD86 and beta2-adrenergic receptor signaling pathways, respectively, increase Oct-2 and OCA-B Expression and binding to the 3'-IgH enhancer in B cells.

Authors:  Joseph R Podojil; Nicholas W Kin; Virginia M Sanders
Journal:  J Biol Chem       Date:  2004-03-15       Impact factor: 5.157

9.  Norepinephrine and epinephrine-deficient mice are hyperinsulinemic and have lower blood glucose.

Authors:  Linda Ste Marie; Richard D Palmiter
Journal:  Endocrinology       Date:  2003-06-26       Impact factor: 4.736

10.  Too much glucagon, too little insulin: time course of pancreatic islet dysfunction in new-onset type 1 diabetes.

Authors:  Rebecca J Brown; Ninet Sinaii; Kristina I Rother
Journal:  Diabetes Care       Date:  2008-07       Impact factor: 19.112

View more
  4 in total

1.  Acute hypoglycemia causes depressive-like behaviors in mice.

Authors:  Min Jung Park; Samuel W Yoo; Brian S Choe; Robert Dantzer; Gregory G Freund
Journal:  Metabolism       Date:  2011-08-04       Impact factor: 8.694

2.  An exploration of the aversive properties of 2-deoxy-D-glucose in rats.

Authors:  Thomas Horman; Maria Fernanda Fernandes; Yan Zhou; Benjamin Fuller; Melissa Tigert; Francesco Leri
Journal:  Psychopharmacology (Berl)       Date:  2018-08-15       Impact factor: 4.530

3.  Engrailed-2 (En2) deletion produces multiple neurodevelopmental defects in monoamine systems, forebrain structures and neurogenesis and behavior.

Authors:  Matthieu Genestine; Lulu Lin; Madel Durens; Yan Yan; Yiqin Jiang; Smrithi Prem; Kunal Bailoor; Brian Kelly; Patricia K Sonsalla; Paul G Matteson; Jill Silverman; Jacqueline N Crawley; James H Millonig; Emanuel DiCicco-Bloom
Journal:  Hum Mol Genet       Date:  2015-07-28       Impact factor: 6.150

4.  Acute Inflammation Alters Brain Energy Metabolism in Mice and Humans: Role in Suppressed Spontaneous Activity, Impaired Cognition, and Delirium.

Authors:  John Kealy; Carol Murray; Eadaoin W Griffin; Ana Belen Lopez-Rodriguez; Dáire Healy; Lucas Silva Tortorelli; John P Lowry; Leiv Otto Watne; Colm Cunningham
Journal:  J Neurosci       Date:  2020-06-08       Impact factor: 6.167

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.